<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806373</url>
  </required_header>
  <id_info>
    <org_study_id>MHS 2020.144</org_study_id>
    <secondary_id>ML42028</secondary_id>
    <nct_id>NCT04806373</nct_id>
  </id_info>
  <brief_title>Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis</brief_title>
  <official_title>Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Healthcare System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to&#xD;
      Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent&#xD;
      pleural effusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol describes a prospective, randomized, double-blind controlled trial comparing&#xD;
      TSP alone to the combination of TSP with cathflo activase for achieving optimal results with&#xD;
      pleurodesis for recurrent pleural effusion. Patients who sign informed consent will be&#xD;
      randomly assigned to receive either TSP alone (talc, 5 gm in 50 ml NS) with placebo (50 ml&#xD;
      NS) or TSP with cathflo activase (4 mg in 50 ml NS) through the chest pleural catheter.&#xD;
      Follow-up lasts for three months. The primary outcome is achievement of a &quot;Radiographically&#xD;
      Satisfactory Pleurodesis&quot; (RSP) by day three post-procedure, defined as chest tube drainage&#xD;
      of less than 100cc over 24 hours and a chest x-ray showing similar or less pleural space&#xD;
      opacification than on the day TSP was performed (baseline, day 0). Secondary outcomes include&#xD;
      the proportion of patients who achieve RSP, time needed to achieve RSP, duration of chest&#xD;
      tube drainage, length of hospital stay after initiation of TSP, proportion of patients&#xD;
      requiring repeat TSP, change in serum hemoglobin during therapy, objective assessments of&#xD;
      pain and dyspnea, and potential complications. This study will recruit 136 patients, with an&#xD;
      interim analyses for efficacy after 50 patients, and aims to help develop the future standard&#xD;
      for management of patients requiring pleurodesis for their symptomatic pleural effusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single center, prospective, randomized, double-blind, placebo-controlled trial with two arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blind. Pharmacist will be unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Positive Change in successful pleurodesis rates</measure>
    <time_frame>3-5 days</time_frame>
    <description>To determine if intrapleural administration of Talc slurry with cathflo activase will improve successful pleurodesis rates compared to talc slurry alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Complications</measure>
    <time_frame>3 months</time_frame>
    <description>To determine if giving cathflo activase with TSP is associated with a higher incidence of complications compared to TSP with placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>Talc Slurry Pleurodesis (TSP) plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who sign informed consent may be randomized to receive TSP alone (talc, 5 gm in 50 ml NS) with placebo (50 ml Normal saline (NS)) through the chest pleural catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Talc Slurry Pleurodesis (TSP) plus Cathflo Activase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who sign informed consent may be randomized to receive TSP (Talc, 5mg in 50ml Normal saline (NS)) with cathflo activase (4 mg in 50 ml NS) through the chest pleural catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cathflo Activase</intervention_name>
    <description>Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter</description>
    <arm_group_label>Talc Slurry Pleurodesis (TSP) plus Cathflo Activase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talc Slurry Pleurodesis</intervention_name>
    <description>Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter</description>
    <arm_group_label>Talc Slurry Pleurodesis (TSP) plus Cathflo Activase</arm_group_label>
    <arm_group_label>Talc Slurry Pleurodesis (TSP) plus placebo</arm_group_label>
    <other_name>TSP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Symptomatic pleural effusion requiring intervention&#xD;
&#xD;
          3. Expected survival &gt; 3 months&#xD;
&#xD;
          4. Written informed consent to trial participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant or lactating&#xD;
&#xD;
          2. Inability to obtain consent from the patient or patient's designated representative.&#xD;
&#xD;
          3. Inability of the patient to comply with the protocol.&#xD;
&#xD;
          4. Previously documented adverse reaction to talc or cathflo activase.&#xD;
&#xD;
          5. Oral or intravenous steroid therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Block, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief, Thoracic Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Candice Sareli, MD</last_name>
    <phone>9542651847</phone>
    <email>csareli@mhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nithya Sundararaman</last_name>
    <phone>9542651846</phone>
    <email>nsundararaman@mhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Healthcare System</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candice Sareli, MD</last_name>
      <phone>954-265-1847</phone>
      <email>csareli@mhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Jianli Niu, MD, PhD</last_name>
      <phone>954-265-6653</phone>
      <email>jniu@mhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Single center study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

